# A Phase Ib/ Ⅱ Clinical Study of MIL62 in Primary Membranous Nephropathy

> **NCT05398653** · PHASE1,PHASE2 · COMPLETED · sponsor: **Beijing Mabworks Biotech Co., Ltd.** · enrollment: 94 (actual)

## Conditions studied

- Primary Membranous Nephropathy

## Interventions

- **DRUG:** MIL62
- **DRUG:** Cyclosporine
- **DRUG:** MIL62

## Key facts

- **NCT ID:** NCT05398653
- **Lead sponsor:** Beijing Mabworks Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-24
- **Primary completion:** 2025-03-04
- **Final completion:** 2025-04-18
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05398653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05398653, "A Phase Ib/ Ⅱ Clinical Study of MIL62 in Primary Membranous Nephropathy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05398653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*